HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy.
BACKGROUND
Factors promoting the emergence of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) connection domain mutations and their effect on antiretroviral therapy (ART) are still largely undetermined. We investigated this matter by analyzing genotypic resistance tests covering 400 amino acid positions in the RT of HIV-1 subtype B viruses and corresponding treatment histories and laboratory measurements.


METHODS
The emergence of connection domain mutations was studied in 334 patients receiving monotherapy or dual therapy with thymidine analogues at the time of the genotypic resistance test. Response to subsequent combination ART (cART) was analyzed using Cox regression for 291 patients receiving unboosted protease inhibitors. Response was defined by ever reaching an HIV RNA level <50 copies/mL during the first cART.


RESULTS
The connection domain mutations N348I, R356K, R358K, A360V, and A371V were more frequently observed in ART-exposed than ART-naive patients, of which only N348I and A360V were nonpolymorphic (with a prevalence of <1.5% in untreated patients). N348I correlated with M184V and predominantly occurred in patients receiving lamivudine and zidovudine concomitantly. A360V was not associated with specific drug combinations and was found to emerge later than M184V or thymidine analogue mutations. Nonpolymorphic connection domain mutations were rarely detected in the absence of established drug resistance mutations in ART-exposed individuals (prevalence, <1%). None of the 5 connection domain mutations associated with treatment showed a statistically significant effect on response to cART.


CONCLUSIONS
Despite their frequent emergence, connection domain mutations did not show large detrimental effects on response to cART. Currently, routine implementation of connection domain sequencing seems unnecessary for developed health care settings.
von Wyl
Viktor
V
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland. vowv@usz.uzh.ch
Ehteshami
Maryam
M
Demeter
Lisa M
LM
Bürgisser
Philippe
P
Nijhuis
Monique
M
Symons
Jori
J
Yerly
Sabine
S
Böni
Jürg
J
Klimkait
Thomas
T
Schuurman
Rob
R
Ledergerber
Bruno
B
Götte
Matthias
M
Günthard
Huldrych F
HF
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001483:Base Sequence; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D005838:Genotype; D054303:HIV Reverse Transcriptase / Q000235:genetics* / Q000378:metabolism; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics; D006801:Humans; D009154:Mutation; D012189:Retrospective Studies
D019380:Anti-HIV Agents; C514824:reverse transcriptase, Human immunodeficiency virus 1; D054303:HIV Reverse Transcriptase